SEARCH · Search PubMed
Results for “ALTITUDE SICKNESS”
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
[Prevention and therapy of acute altitude sickness].
Explore the source record for details and available documents.
[Prevention and therapy of altitude sickness].
Climbing in the Alps and trekking in the Andes or in the Himalayas became more and more popular in the last years. This is the reason why more and more tourists develop symptoms of acute mountain sickness (AMS) at an altitude higher than 2500 m a.s.l. To avoid an unpleasant stay at altitude, an accurate acclimatization is necessary. This can be achieved by a slow ascent at a climbing rate of 300 to 600 m in one day. If that is not possible, climbers should spend at least nine or more nights at an altitude higher than 2500 m a.s.l. in the last 30 days before ascent. This would improve performance at high altitude and significantly decrease symptoms of AMS. If acclimatization for one or another reason may not be possible or if somebody is still susceptible to AMS, pharmacological prophylaxis and treatment can be used. Drug of first choice for AMS prophylaxis is acetazolamide, a carboanhydrase inhibitor who increases ventilation. Acetazolamide has been used in a dosage of 250 to 500 mg 12 to 24 h. before ascent. If climbers have a history of high-altitude pulmonary edema (HAPE), nifedipine, a potent vasodilator which decreases pulmonary artery pressure, is the drug of the first choice and should be taken in a dosage of 3 x 20 mg, beginning one day before climbing and continuing during climbing. Prophylactic administration of nifedipine has no effect on symptoms of AMS in subjects who are not susceptible to HAPE.(ABSTRACT TRUNCATED AT 250 WORDS)
James Glaisher's 1862 account of balloon sickness: altitude, decompression injury, and hypoxemia.
In 1862, James Glaisher and Henry Coxwell ascended to 29,000 feet in an open hot-air balloon. During the ascent, Glaisher described marked neurologic compromises: appendicular and later truncal paralysis, blindness, initially preserved cognition, and subsequent loss of consciousness. The author examines Glaisher's account of balloon sickness by comparing it with other balloonists' observations and discussing it in the context of altitude sickness, decompression injury, and hypoxemia.
JAMA patient page. Altitude sickness.
Explore the source record for details and available documents.
[Comment on F. Berghold, W. Schaffert and K. Pallasmann: Prerequisites and guidelines for acclimatization to great and extreme altitude in prevention of altitude sickness].
Explore the source record for details and available documents.
[Advantages of delayed-action Pervincamine Forte in the prevention of altitude sickness].
Explore the source record for details and available documents.
Altitude sickness (seroche). An experience in acclimatization to high altitude.
Explore the source record for details and available documents.
[The oral therapy of "altitude sickness" with micoren].
Explore the source record for details and available documents.
[Pathophysiology and therapy of altitude sickness].
Explore the source record for details and available documents.
[Acute altitude sickness].
Explore the source record for details and available documents.